• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Brain Cancer Drug Pipeline Update 2015

  • ID: 1197077
  • June 2015
  • Region: Global
  • Bioseeker

Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available.
There are today 289 companies plus partners developing 374 drugs targeting brain cancer in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 95 drugs. Brain Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 217 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 210 out of the 210 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized READ MORE >

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Novartis AG Qiagen N.V. Elekta AB Roche Diagnostics Ltd. Bristol-Myers Squibb Genentech, Inc.